Iguratimod can also control rheumatoid arthritis (RA) and bone loss caused by RA by inhibiting IL-1β, TNF-α, IL-6, IL-8, MPC-1, and other cytokines from synthesizing, so as to prevent bone absorption and promote bone formation. Here, IL6 is linked to rheumatoid arthritis.